Assessing the Reach, Effectiveness, and Implementation of Multiple Harm Reduction Interventions.
Project Number3R01DA057613-01S1
Former Number1R01DA057613-01
Contact PI/Project LeaderKRAL, ALEXANDER H
Awardee OrganizationRESEARCH TRIANGLE INSTITUTE
Description
Abstract Text
We propose to assess the influence of criminal legal systems (CLS) on the use of harm reduction services (HRS) and overdose mortality among people who use drugs (PWUD). To accomplish this, we build off Aim 1 and Aim 2 of the parent grant (R01DA057613). Like many states and municipalities across the nation, San Francisco (SF) has confronted the rise in overdose deaths by increasing police enforcement of drugs, including interdiction efforts with drugs being seized by police. However, the criminalization of drug use may pose significant barriers to the use and success of HRS and can exacerbate the risk of overdose. This can occur directly through CLS involvement but also indirectly through police efforts to disrupt unregulated drug markets. Additionally, fear of police, particularly for those under CLS supervision, may deter people from
traveling to and from HRS sites. We have recently demonstrated the indirect influence of CLS on overdose in what we describe as the “Drug Bust Paradox,” which shows that police efforts to disrupt drug markets in Indianapolis was associated with significant increases in fatal overdose. We propose to test both the direct and indirect influence of CLS on the use of HRS and on overdose among PWUD in SF. For direct CLS involvement we will examine the large sample (N>1,200) of survey data collected from PWUD in the parent R01 project in SF. Along with geospatial measures of where people use drugs, the number of suppliers they buy drugs from, and detailed use of all HRS, these data also include metrics of CLS involvement that were
developed as part of NIDA’s Harm Reduction Research Network (HRRN) data harmonization initiative. The investigative team has leveraged existing collaborations with the SF Police Department and the Department of Public Health to acquire crime and overdose mortality data to replicate, improve, and further test the indirect effect of CLS efforts to disrupt unregulated drug markets on overdose. We propose: Aim 1: Assess direct CLS involvement on the use of HRS. Using the PWUD Survey Data from the parent project, we will examine whether the CLS metrics developed by the HRRN are associated with lower use of HRS. Aim 2: Assess indirect CLS influence on drug supply disruptions. The PWUD Survey Data from the parent grant includes geospatial information on where people use drugs and from how many people they bought
drugs. Using the administrative data, we will assess whether drug seizures are associated with PWUD needing to access drugs from more suppliers. Aim 3: Assess protective factors of harm reduction services in the association of drug supply disruption with overdose mortality. Using point-level information on drug seizures, we will use a contagion modeling approach to estimate whether CLS efforts to disrupt the unregulated drug supply affects the spread of overdose mortality events while adjusting for community-level factors, including distance to HRS. This administrative supplement will fund planning, analysis, writing, and dissemination to achieve these three aims.
This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to improve treatment for opioid misuse and addiction.
Public Health Relevance Statement
PROJECT NARRATIVE
This administrative supplement project examines whether criminal legal system involvement impedes the
reach of harm reduction services and exacerbates overdose mortality. This evaluation could help clarify for
policymakers and service providers what practices or barriers need to be adapted to improve the health of
people who use drugs. These findings are critical for public health and public safety agencies who continue to
struggle with solutions that reduce overdose mortality in the United States.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAdministrative SupplementAffectAnticonvulsantsCollaborationsCommunitiesCrimeDataDrug usageDrug userEffectivenessEpidemiologistEquityEvaluationEventFrightFundingFutureHarm ReductionHealthIllicit DrugsImprisonmentInternationalInterventionInvestigationLegal systemManuscriptsMeasuresMedical ExaminersMetric SystemModelingMunicipalitiesNational Institute of Drug AbuseOutcomeOverdoseOverdose reductionParentsPeer ReviewPersonsPharmaceutical PreparationsPolicePolicy MakerPredispositionPublic HealthReach, Effectiveness, Adoption, Implementation, and MaintenanceRecording of previous eventsResearchResearch PersonnelSafetySamplingSan FranciscoServicesSiteSmokeSupervisionSurveysTestingTimeTravelUnited StatesWritingcommunity-level factorcontagiondata harmonizationdrug marketeffectiveness evaluationimprovedinnovationmortalityopiate toleranceoverdose deathoverdose riskparent grantparent projectprotective factorsservice providerssuccess
No Sub Projects information available for 3R01DA057613-01S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01DA057613-01S1
Patents
No Patents information available for 3R01DA057613-01S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01DA057613-01S1
Clinical Studies
No Clinical Studies information available for 3R01DA057613-01S1
News and More
Related News Releases
No news release information available for 3R01DA057613-01S1
History
No Historical information available for 3R01DA057613-01S1
Similar Projects
No Similar Projects information available for 3R01DA057613-01S1